Prevalence and clinical factors associated with survival in patients with egfr-mutated lung cancer in argentina

HIGHLIGHTS

• What: To detect a difference between the first and second-generation TKI groups compared to Osimertinib, assuming an anticipated hazard ratio (HR) of 0.5 based on prior studies, the authors aimed to observe a total of 66 progression events. It has a unique repository of information for each patient centralised through an electronic health record, in which patients have voluntarily and certifiedly signed informed consent for the use of their data for research purposes. The main reasons for patient exclusion were either not receiving TKI treatment or lack of follow-up at HIBA. A Cox regression . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.